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Open access under the ElIn this study the mutagenic, recombinagenic, carcinogenic and anticarcinogenic potential of orlistat was
assessed using the somatic mutation and recombination test (SMART) and the epithelial tumor detection
test (wts). The experiments were conducted on Drosophila melanogaster. In the assessment using SMART,
larvae, descendants from the standard (ST) cross and the high bioactivation (HB) cross, were treated
chronically with three orlistat concentrations. The results revealed a recombinagenic effect, associated
with orlistat, in the descendants of the HB cross, at all three levels of concentration. Homologous recom-
bination can function as a determinant at different stages of carcinogenesis. For veriﬁcation, larvae from
the wts test, descendants of the wts/TM3 virgin female and mwh/mwh male cross, were treated with the
same three orlistat concentrations separately and in association with mitomicin C (0.1 mM). The results
did not, however, provide evidence that orlistat has carcinogenic potential nor was it associated with the
reduction of tumors induced by mitomicin C in D. melanogaster.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Orlistat (Xenical) is the most stable, partially hydrolyzed
semi-synthetic analog of lipstatin, produced by Streptomyces toxy-
tricini (Mancini and Halpern, 2002; Menendez et al., 2005;
Al-Suwailem et al., 2006). Orlistat and sibutramine are the only
medications approved by the FDA (Food and Drug Administration)
for long-term obesity treatment (Fortes et al., 2006). Orlistat is a
powerful and speciﬁc inhibitor of the gastric and pancreatic lipases
that acts in the region of the intestinal lumen, with minimal
absorption (Ullrich et al., 2003; Bray, 2009; Coutinho, 2009; Kazmi
et al., 2009). When linked to the lipase site of action, orlistat forms
a stable complex that induces a conformational change in the
enzyme, exposing and deactivating its active catalytic site.
Deactivated lipase cannot hydrolyze fats to fatty acids and mono-
glycerides. Thus the fat passes through the gastrointestinal tract
and is eliminated in unaltered form, in the feces (Mancini and
Halpern, 2002; Al-Suwailem et al., 2006). The caloric deﬁcitdants; CYP3A4, cytochrome
enzyme; FDA, Food and Drug
tion cross; MH, marked trans
tic mutation and recombina-
tection test.
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ceno).
sevier OA license.resulting from the non-absorption of triglycerides may have a po-
sitive impact on body weight control (Ballinger and Peikin, 2002;
Coutinho, 2009).
Recent research has shown orlistat to be a powerful growth
inhibitor of some tumors. It has been demonstrated that it has
anti-proliferative and antitumoral properties for prostate and
breast cancer cells because of its ability to block the activity of
the fatty acid synthase enzyme (FAS) (Menendez et al., 2005). By
inhibiting fatty acid synthesis, orlistat paralyzes tumor cell prolif-
eration, inducing apoptosis and inhibiting tumor growth (Kridel
et al., 2004). However, there are no results from long-term studies
with this drug and little is known about possible genotoxic effects
associated with its use.
Although homologous recombination is an important process
for DNA repair, there is growing evidence that deleterious genomic
rearrangements may result from homologous recombination,
which means that homologous recombination events may be
determinant in carcinogenesis (Arossi et al., 2009). The transforma-
tion of normal cells into cancer cells is a multistep process. Mitotic
recombination is a mechanism involved in bringing about such
transformation (Nowell, 1976; Barrett, 1993). In heterozygous cells
bearing both mutant and normal alleles for a tumor suppressor
gene, the somatic recombination may be a promoter of neoplasms
by inducing homozygosis of the mutant tumor suppressor allele
(Maher et al., 1993; Sengstag, 1994).
Genetic toxicology is an important area of the science that stud-
ies the genotoxic/mutagenic properties of agents (chemical,
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various assays to assess the damage that these may cause to the
DNA, in the presence or absence of mass metabolism systems
(Fonseca and Pereira, 2004). These assays include the SMART (so-
matic mutation and recombination test), developed by Graf et al.
(1984). The use of SMART on Drosophila melanogaster wings can
detect a wide spectrum of genetic abnormalities such as mutation,
deletion and recombination (Graf et al., 1984).
In this test ﬂies, carriers of the mwh and ﬂr3 marker genes, are
used and the alterations are detected by heterozygous loss in these
genes. During the D. melanogaster embryonic development, the
imaginal disc cells proliferate mitotically to form the body of the
adult ﬂy. Genetic alterations in some of these cells lead to the for-
mation of mutant cells that are detected as wing-hair mutation
spots on the adult ﬂy (Guzmán-Ricon and Graf, 1995). In the same
way that there are tests used in the mutagenic assessment of
chemical, natural and synthetic agents, there are also tests that
are applied to assess the carcinogenic potential of these agents,
including the test to detect epithelial tumor clones (wts), also per-
formed on D. melanogaster (Eeken et al., 2002).
The evolutionary conservation of tumor-suppressor genes
among Drosophila and mammals has prompted studies of tumor
induction and development in Drosophila, studies that contribute
to the understanding of cancer in human beings (Potter et al.,
2000; Eeken et al., 2002). The wts gene was identiﬁed based on
its ability to act as a tumor suppressor in Drosophila (Nishiyama
et al., 1999). Deletion of this gene leads to the formation of clones
with circular cells that are considerably invasive, commonly called
warts, that develop throughout the ﬂy body (Justice et al., 1995).
The growing consumption of orlistat by the global population
and the easy acquisition of this drug because its use no longer re-
quires medical prescription, have increased interest in assessing
possible genotoxic and/or carcinogenic effects associated with its
use. Thus the objective of the present study was to assess the
mutagenic, recombinagenic and carcinogenic potential of orlistat
using the SMART and epithelial tumor detection test (wts), both
carried out on D. melanogaster.2. Materials and methods
2.1. Chemical agents
Three different concentrations of orlistat (Xenical) (2.4, 4.8, and 9.6 mg/mL),
batch number B2106/02, produced by Roche Produtos Farmacêuticos S.A., Rio de
Janeiro, Brazil, were prepared for the treatment. Each capsule of Xenical contained
120 mg of orlistat (CAS 96829-58-2) with P99.5% pure product. Fig. 1 shows the
chemical structure of the test compound.
Flasks of 10 mg freeze-dried doxorubicin hydrochloride (DXR), commonly
known as Doxolen, batch number 83520, with 580.0 molecular weight,
(C27H29NO11HCl) (CAS 23214-92-8), manufactured by Eurofarma Laboratórios LtdaFig. 1. Chemical structure of the orlistat.and distributed by Zodiac Produtos Farmacêuticos S.A., São Paulo, Brazil, were used
in a concentration of 0.125 mg/mL for the treatment. Each ampoule of Doxolen con-
tained 10 mg of chlorohydrate of DXR, 1 mg methylparaben, and 50 mg lactose.
Ampoules of Mitocin (Mitomicin C – CAS 50-07-7), containing 5 mg of freeze-
dried powder for injectable solution, batch number 9H48931, manufactured by Kyo-
wa Hakko Kirin, Japan and imported by Bristol-Myers Squibb Farmacêutica, São Pau-
lo, Brazil, were used in a concentration of 0.1 mM. The concentration used in this
experiment was based on studies of the mitotic recombination in D. melanogaster
(third instar larvae), induced by mitomicin C (Tsuda and Takeda, 1987).
2.2. Somatic mutation and recombination test (SMART) in D. melanogaster
2.2.1. Stock strains, crosses and treatment
Three mutant D. melanogaster lines were used to conduct this test:mwh, ﬂr3 and
ORR, carriers of the multiple wing hairs (mwh, 3-.3) and ﬂare-3 (ﬂr3, 3–38.8) marker
genes. These lines were kept in stock in 1=4 L ﬂasks containing culture medium for D.
melanogaster [820 mL water, 25 g yeast (Saccharomyces cerevisiae), 11 g agar, 156 g
banana and 1 g nipagin] at 25 C and 65% relative humidity.
Two types of crosses were made: (1) standard (ST) cross, in which ﬂr3 /In(3
LR)TM3, ri pp sep I(3)89Aa bx34e and Bds virgin females were crossed with
mwh/mwh males (Graf et al., 1989); and (2) high bioactivation (HB) cross, in which
ORR/ORR; ﬂr3/In(3 LR)TM3, ri pp sep I(3)89Aa bx34e and Bds virgin females were crossed
with mwh/mwh males (Graf and Van Schaik, 1992).
Eggs were collected from the descendants of the ST and HB crosses during an
8 hour period in ﬂasks containing a solid agar base (3% agar in water) and a layer
of biological yeast supplemented with sucrose. After 72 ± 4 h the larvae were
washed with reverse osmosis water and collected using a ﬁne mesh sieve.
The larvae collected were placed in glass ﬂasks containing 1.5 g of instant
mashed potatoes (HIKARI brand, São Paulo, Brazil) culture medium. Five milliliters
of orlistat were added to each ﬂask at different concentrations, diluted in 5% etha-
nol. Doxorubicin (DXR 0.125 mg/mL) was used for positive control and 5% ethanol
for the negative control.
Third stage larvae were submitted to a chronic treatment for approximately
48 h during which time they climbed the walls of the ﬂasks, passing to the pupa
stage.
2.2.2. Slide preparation and microscopic analysis
The emergent adults from both crosses (ST and HB), carriers of the MH (mwh +/+
ﬂr3) trans heterozygote and BH (mwh +/+ TM3, Bds) balanced heterozygote geno-
types, were collected and preserved in 70% ethanol. The preserved ﬂy wings were
placed under a stereoscopic microscope using entomological pincers and the wing
pairs were spread over codiﬁed slides. A Faure solution (30 g gum Arabic, 20 mL
glycerol, 50 g chloral hydrate, and 50 mL distilled water) was used to ﬁx the wings.
After mounting, the slides remained on a warm plate (60 C) for 1 h.
An optical light microscope (400 magniﬁcation) was used for the wing micro-
scopic analysis. The number of spots, spot type (single or twin) and the positions of
the spots on the wings were recorded.
2.2.3. Statistical analysis
The mutagenic/recombinagenic effect of orlistat was assessed using Kasten-
baum and Bowman’s binomial conditional test, described by Frei and Würgler
(1988). The Mann, Whitney or Wilcoxon nonparametric U test was used to exclude
false positive results (Frei and Würgler, 1995), at the a = 0.05 level of signiﬁcance.
Based on the number of the mwh clones, it was possible to calculate the induc-
tion frequency per cell. For chronic treatment Frei andWürgler (1988) estimated an
integral induction frequency per cell and per cell division. This frequency is the
number of mwh clones divided by the number of cells examined per ﬂy (48,000).
2.3. Detection of epithelial tumors in D. melanogaster
The wts marker is a lethal recessive mutation during homozygosis, in the zy-
gotes. Due to its lethalness, this allele is kept in the stock line with the presence
of a chromosome balancer (TM3). Heterozygous larvae are obtained by crossing
wts/TM3 with mwh/mhw strain (wts/+). Heterozygous loss in the cells of the
Drosophila imaginal disks also is associated with homozygous clone formation (via-
ble in isolated cell sets) in the larvae, manifested as tumors in the adult ﬂies (Sido-
rov et al., 2001).
2.3.1. Stock strains, crosses and treatment
Two mutant D. melanogaster strains were used for the experiments: (1) wts/
TM3, Sb1. This strain presents one lethal wart (wts) on chromosome 3, balanced
by the TM3 chromosome, with multiple inversions characterized by the dominant
stubble (Sb) mutation, phenotypically identiﬁed by short bristles. This strain was
provided by Bloomington Drosophila Stock Center of the University of Indiana,
USA: (Bloomington/7052); (2) multiple wing hairs (mwh/mwh). Flies of the mwh
strain have a marker gene on chromosome-3 (3–0.3) in a distal position, with three
or more hairs in each cell. The strain is kept in homozygosis since it is a viable
mutation. It was provided by Dr. Ulrich Graf (Physiology and Animal Husbandry,
2600 P.C. Orsolin et al. / Food and Chemical Toxicology 50 (2012) 2598–2604Institute of Animal Science, ETH Zurich, Schwerzenbach, Switzerland). The stocks
containing these strains were also kept in 1=4 L ﬂasks containing culture medium
for D. melanogaster at 25 C and 65% relative humidity.
To obtain wts +/+ mwh heterozygotic larvae, virgin females wts/TM3, Sb1 (Eeken
et al., 2002) were crossed with mwh/mwh males (Costa et al., 2011). The eggs of the
descendants were collected during an 8 h period. After 72 ± 4 h, third-instar larvae
were washed in reverse osmosis water and collected using a ﬁne mesh sieve. The
larvae from this cross were treated with the orlistat compounds. The larvae were
placed in glass ﬂasks containing 1.5 g mashed potatoes and 5 mL orlistat at the dif-
ferent concentrations explained, diluted in 5% ethanol. The larvae were submitted
to a chronic treatment for approximately 48 h. Mitomicin C (0.1 mM) was used
for the positive control and 5% ethanol for the negative control. The larvae exposed
to mitomicin C, either in association or not, were pre-treated (for 6 h). However,
only adult ﬂies, without the chromosome balancer (TM3, Sb1) were analyzed. It
was found that they did not have truncated bristles.
2.3.2. Scoring of warts
Following metamorphosis, the adult ﬂies were transferred to recipients contain-
ing 70% ethanol. Later the males and females of the (wts +/+ mwh) genotype, which
had wild hairs (long and thin) were analyzed for tumor (wart) presence. The ﬂies
were observed using a stereoscopic magnifying glass and entomological tweezers.
Only tumors that were large enough to be unequivocally classiﬁed were recorded.
The tumor frequency was calculated as the number of tumors/number of wts +/+
mwh ﬂies (Eeken et al., 2002).
2.4. Statistical analysis
The orlistat carcinogenic potential was identiﬁed by the Mann, Whitney and
Wilcoxon nonparametric U test, using a = 0.05 level of signiﬁcance.
3. Results and discussion
All of the compounds were tested in two different experiments.
The data were pooled after verifying that the two independent
experiments were in agreement with acceptable reproducibility.
No signiﬁcant decreases in the survival rates of larvae submitted
to treatments were observed when compared to the negative con-
trol. The results obtained showed a statistically signiﬁcant increase
in the small single spot, large single spot, twin spot and total spot
frequencies in the MH descendants, both for the ST and HB crosses
treated with DXR (0.125 mg/ml). This increase in the mutant spot
frequencies reinforced previous research as to the genotoxicity of
the orlistat compound. Its principal effect is, thus, recombinagenic,
veriﬁed in the descendants of the BH line. This strong recombina-
genic activity of DXR in D. melanogaster somatic cells, using the
same dose, had previously been described by Lehmann et al.
(2003), Costa and Nepomuceno (2006), Fragiorge et al. (2007),
Castro et al. (2008) and Costa et al. (2011).
As seen in Table 1, there was no statistically signiﬁcant increase
in the marked trans heterozygous descendants (MH) of the stan-
dard cross (ST) or in the total number of spots at any of the threeTable 1
Frequency of mutants spots observed in the marked trans-heterozygous descendants (MH)
orlistat concentrations (2.4, 4.8 and 9.6 mg/mL), positive control (DXR 0.125 mg/mL) and
Treatments
(mg/mL)
Number of
ﬂies (N)
Spots per ﬂy (No. of spots); statistical diagnosisa
Small single (1–2
céls)b m = 2
Large single (>2
céls)b m = 5
Twin
m = 5
mwh/ﬂr3
Ethanol 5% 60 0.57 (34) 0.03 (2) 0.02 (1)
DXR 60 0.93 (56) + 0.27 (16) + 0.35(21)+
2.4 50 0.84 (42) i 0.06 (3) i 0.02 (1) i
4.8 60 0.58 (35)  0.05 (3) i 0.00 (0) i
9.6 50 0.72 (36)  0.06 (3) i 0.04 (2) i
m =multiplication factor for signiﬁcantly negative results. Level of signiﬁcance a = 0.05.
a Statistical diagnostic according to Frei and Würgler (1988): (+) positive (compared
b Including rare single ﬂr3 spots.
c Considering the mwh clones for the single spots and mwh for the twin spots.
d Frequency of clone formation: clones/ﬂies/48,800 cells (without size correction).orlistat concentrations, compared with the spot frequencies ob-
served in the negative control. For this reason, the balanced hetero-
zygous descendants (BH) were not analyzed.
The inﬂuence of differences in the level of cytochrome P450 on
the genotoxic properties of orlistat using the high bioactivation
(HB) cross of Drosophilawas also investigated. The HB cross is char-
acterized by an increase in cytochrome P450-dependent bioactiva-
tion capacity for promutagens as compared with that of the ST. The
results, shown in Table 2, indicate statistically signiﬁcant increases
in the small single spot and total mutant spot categories at all three
of the orlistat concentrations tested. It was concluded that orlistat
has an indirect genotoxic effect at these three concentrations. It is
suggested, therefore, that cytochrome P450 enzymes interfered in
the genotoxicity of this compound in D. melanogaster. Several ani-
mal studies have shown that orlistat absorption is minimal and it is
excreted extensively, in unaltered form, in the feces (Silva et al.,
2002; Al-Suwailem et al., 2006; Kazmi et al., 2009). Under normal
circumstances, due to the extensive metabolism of the ﬁrst passage
and high systemic clearance mediated by CYP3A4 in the intestine
and liver, low orlistat plasmatic concentrations are reached. This
drug is metabolized mainly by the gastrointestinal wall (pre-sys-
temic metabolism), resulting in two larger metabolites, M1
(4-member hydrolyzed lactone ring) and M3 (M1 with N-formyl
leucine moiety cleaved), detected in minimal plasmatic concentra-
tions and considered pharmacologically inactive (Silva et al., 2002).
It was thus expected that biotransformation would not directly
affect the orlistat genotoxicity.
The mechanisms by which orlistat induces DNA damage were
not directly assessed in the present research. It is believed, how-
ever, that this damage may be associated in some way with free
radical generation. Guzmán et al. (2011) evaluated the effect of
orlistat on oxidative stress in rat brain. The researchers found that
orlistat possesses pro-oxidant activities induced by a decrease of
glutathione (GSH) and serotonin (5-HT). According to Garcia
et al. (2006), intra-luminal fat accumulation in the colon, resulting
from the orlistat action, intensiﬁes the formation of oxygen reac-
tive species in the feces. The main damage caused by these oxyrad-
icals is lipidic peroxidation that they stimulate. This occurs when
excessive hydroxyl radical production in the proximities of the
membranes enables the fatty acid to attack the phospholipidic
membrane, producing lipid hydroperoxides. The accumulation of
these agents generates oxidative damage that can inactivate the
membrane and culminate in cell death. The lipid hydroperoxides
can also decompose and produce a variety of cytotoxins.
The possibility of decreased antioxidant defense, resulting from
the reduced absorption of the fat soluble vitamins, cannot beof Drosophila melanogaster derived from the standard cross (ST) treated with different
negative control (5% ethanol).
Spots with mwh
clonec (n)
Mean clone size
classc,d (î)
Frequency of clone
formation/105 cells per
cell divisiond
Total spots
m = 2
Observed Control
corrected
0.62 (37) 36 1.42 1.23
1.55 (93) + 91 2.57 {3.33} 3.11 {1.88}
0.92 (46)  44 1.55 {1.82} 1.80 {0.57}
0.63 (38)  38 1.39 {1.00} 1.30 {0.07}
0.82 (41)  41 1.59 {2.05} 1.68 {0.20}
to the negative control); () negative; (i) inconclusive.
Table 2
Frequency of mutants spots observed in the marked trans-heterozygous descendants (MH) and balanced heterozygotes (BH) of Drosophila melanogaster, derived from the High
Bioactivation Cross (HB) treated with different orlistat concentrations (2.4, 4.8, and 9.6 mg/mL), positive control (DXR 0.125 mg/mL) and negative control (5% ethanol).
Treatments
(mg/mL)
Number of
ﬂies (N)
Spots per ﬂy (No. of spots); statistical diagnosisa Spots with mwh
clonec (n)
Mean clone size
classc,d (î)
Frequency of clone
formation/105 cells per
cell division
Small single spots
(1–2 céls)b m = 2
Large single spots
(>2 céls)b m = 5
Twin m = 5 Total
spots
m = 2
Observed Control corrected
mwh/ﬂr3
Ethanol 5% 60 1.12 (67) 0.13 (08) 0.03 (02) 1.28 (77) 77 1.84 2.63
DXR 60 2.15 (129) + 0.72 (43) + 0.40 (24) + 3.27 (196) + 188 2.38 {2.76} 6.42 {3.79}
2.4 60 1.80 (108) + 0.07 (04)  0.02 (01) i 1.88 (113) + 113 1.39 {0.42} 3.86 {1.23}
4.8 60 1.87 (112) + 0.10 (06) i 0.03 (02) i 2.00 (120) + 120 1.56 {1.05} 4.10 {1.47}
9.6 60 1.83 (110) + 0.08 (05)  0.00 (00) i 1.92 (115) + 115 1.47 {0.71} 3.93 {1.30}
mwh/TM3
Ethanol 5% 20 0.40 (8) 0.00 (0) 0.40 (8) 8 1.38 0.88
DXR 20 0.65 (13) 0.00 (0) i 0.65 (13) 13 1.38 {1.40} 1.33 {0.51}
2.4 20 0.65 (13) + 0.00 (0) i 0.65 (13) + 13 1.15 {0.80} 1.33 {0.51}
4.8 20 0.55 (12) i 0.00 (0) i 0.55 (12) i 12 1.27 {1.00} 1.13 {0.31}
9.6 20 0.60 (11) i 0.00 (0) i 0.60 (11) i 11 1.17 {0.75} 1.23 {0.41}
m = multiplication factor for signiﬁcantly negative results. Level of signiﬁcance a = 0.05.
a Statistical diagnostic according to Frei and Würgler (1988): (+) positive (compared to the negative control); () negative; (i) inconclusive.
b Including rare single ﬂr3 spots.
c Considering the mwh clones for these single spots and mwh for the twin spots.
d Frequency of clone formation: clones/ﬂies/48,800 cells (without size correction).
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can simultaneously have signiﬁcant effects on fat soluble vitamin
absorption, especially antioxidant vitamins such as A and E
(Ozcelik et al., 2005; Fortes et al., 2006). The role of these vitamins
is widely recognized in genetic damage prevention because they
block increases in DNA lesions that have resulted from the appear-
ance of oxygen reactive species (Nepomuceno, 2011). Therefore, in
the absence of the anti-oxidant vitamins, the organism becomes
more vulnerable to oxidative damage to the DNA.
In view of the positive results for orlistat genotoxicity at the
three tested concentrations, the BH (mwh/TM3) descendants from
the HB cross treated with these concentrations were analyzed to
calculate the percentage of recombinagenic and mutagenic events.
In this context, the different concentrations of the doses used for
orlistat made it difﬁcult to compare their genotoxicity levels. Thus,
following the method described by Frei and Würgler (1995) and
amply used by other authors (Cunha et al., 2002; Franchi et al.,
2009), the standardized clone induction frequency per unit of
exposure (mg/mL) was established. Calculations were made, cor-
recting themwh clone numbers in the two genotypes at each expo-
sure level. Not only the control frequencies but also the numbers of
ﬂies analyzed in the different treatment series were used as bases
for this correction. Subsequently, as suggested Franchi et al. (2009),
using a combination of the results from different exposure levels
via linear extrapolation, an approximate average induction fre-
quency per unit of exposure concentration was calculated.
The results are shown in Table 3 as standardizedmwh clone for-
mation frequencies per mg/mL concentration per cell and per cell
division. Orlistat produced 0.67 clones per 105 cells per mg/mL in
the marker-heterozygous (MH) genotypes. From this observation,
we can conclude that orlistat is not a strongly genotoxic drug.
The clone formation frequencies determined for both genotypes
permit quantitation of the recombinagenic action of this drug.
Approximately 70% of the mutant clones induced by orlistat were
related to its mitotic recombination action. This suggests that
orlistat may provoke genomic instability through the induction
of homologous recombination.
Data in the literature conducted with other test organisms have
suggested that orlistat is not mutagenic. Lopes and Vicentini
(2002), in a study carried out to assess the mutagenesis of Xenical
(orlistat), used cells of Wistar rat (Rattus norvegicus) bone marrowas test material, treated in vivo by gavage. The authors observed an
absence of mutagenic effects at the three orlistat concentrations
(0.2, 0.4 and 0.6 mg/mL). It should be noted, however, that the
doses used in the research cited were considerably lower than
those used in the present study. On the other hand, studies con-
ducted by Ahmed and Ghaly (2011), which included the micronu-
cleus test and chromosomal aberration assay, using doses
comparable to those proposed for human therapeutic and double
therapeutic doses, revealed that the total number of structural
chromosomal aberrations in bone marrow cells, with gap, was sig-
niﬁcantly increased in association with the therapeutic doses.
Since we have shown that the drug is not strongly genotoxic, it
is also important to emphasize that most of the bioassays used to
assess genotoxicity are limited to detecting mutagenic effects. But
not every alteration in the genetic material is essentially a muta-
tion. Recent evidence has suggested that homologous recombina-
tion is one of the main processes of genetic alterations (Andrade
and Lehmann, 2003; Erdtmann, 2003). Homologous recombination
consists of an errant repair mechanism in the DNA that can lead to
heterozygote loss or genetic rearrangements and is crucial in the
genesis of innumerable genetic diseases such as cancer (Sinigaglia
et al., 2004). SMART is an important tool in this context, because it
allows not only assessment of mutational events, but also the
assessment of recombinagenic events, as shown in the present
study.
Although homologous recombination is an important process of
DNA repair, there is growing evidence that deleterious genomic
rearrangements may result from homologous recombination. This
means that homologous recombination events may play a causa-
tive role in carcinogenesis (Arossi et al., 2009). The transformation
of normal cells into cancer cells is a multistep process. While mito-
tic recombination is a mechanism involved in bringing about such
transformation (Nowell, 1976; Barrett, 1993), in heterozygous cells
bearing mutant and normal alleles for a tumor suppressor gene,
the somatic recombination may act as a promoter of neoplasms
by inducing homozygosis of the mutant tumor suppressor allele
(Maher et al., 1993; Sengstag, 1994).
To verify whether the alterations in DNA induced by orlistat
were not only recombinagenic activity but also inducers of tumor
formation a test was conducted to detect epithelial tumor clones
(wts) in D. melanogaster. The results showed that there was no
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found at the three tested orlistat concentrations (alone) and the
negative control, thus suggesting an absence of carcinogenic po-
tential of orlistat (Table 4).
Similarly, when assessing the orlistat and MMC associations, it
was observed that there was no signiﬁcant difference among the
tumor frequencies found at the three orlistat concentrations asso-
ciated with MMC and the frequencies found in the individuals trea-
ted only with MMC. It was concluded, therefore, that orlistat did
not reduce the appearance of MMC induced tumors in D. melano-
gaster and also did not have anti-carcinogenic effects.
It is relevant to emphasize that a pre-treatment systemwas car-
ried out with MMC on the larvae treated with the orlistat–MMC
association. Orlistat was used after the treatment with MMC to
verify whether it was capable of inhibiting tumors already induced,
as described by other authors (Kridel et al., 2004; Menendez et al.,
2005). MMC was chosen as the agent for the present research but
the results obtained reﬂected the action of orlistat in relation to tu-
mor inhibition generally, regardless of the action mechanism and
the tumor induction agent used. The signiﬁcant results for tumor
frequency in the individuals treated with MMC alone conﬁrmed
that this drug induced tumors in D. melanogaster, thus validating
the test and the results obtained.
Although the results of the present study indicated an absence of
anti-carcinogenic effects generated by orlistat, recent research has
suggested that orlistat acts as a potent tumor growth inhibitor, espe-
cially in the prostate and breast. This anti-proliferative activity
would be associatedwith the capacity of orlistat to block the activity
of the fatty acid synthase enzyme. Kridel et al. (2004) found that orli-
stat is a powerful inhibitor of the FAS tioesterase dominion, an en-
zyme strongly linked to tumor progression. As a result of its
capacity to inhibit fatty acid synthesis, orlistat paralyzes tumor cell
proliferation, inducing these cells to apoptosis and inhibiting tumor
growth in nude mice. Menendez et al. (2005) assessed the anti-tu-
mor action of Orlistat in breast cancer cells and reported a similar ef-
fect. Orlistat induced, in a dose-dependent manner, signiﬁcant
alterations in the distribution of cancerogenous cell populations
and it blocked the cell cycle progression and promoted cell death
by apoptosis. Browne et al. (2006) also veriﬁed that orlistatwas cyto-
toxic for tumor cells. The authors concluded that this drug, by inhib-
iting FAS in the endothelial cells and blocking fatty acid synthesis,
hindered cell proliferation and consequently inhibited angiogenesis.
It should be considered, however, that there are various genes
involved in cancer genesis and progression and the fact that the re-
sults of the present research demonstrated an absence of anti-
carcinogenic effects by orlistat in relation to the wts gene (tumor
suppressor) does not necessarily mean that these effects can be
generalized to other genes involved in the process. Furthermore,
it is pertinent to highlight that the descendants analyzed in the
wts test had low cytochrome P450 levels and the positive results
for orlistat recombinagenicity (using SMART) occurred in the
descendants of the HB cross, which had high cytochrome P450 lev-
els. For this reason we can assume that the results reported here
would have been different if the descendants observed in the wts
line had presented high cytochrome P450 levels.
Although there are many reports in the literature that orlistat
acts as a potent FAS inhibitor in some types of tissues, resulting
in the deaths of several tumors cells (Chuang et al., 2011), there
are other factors resulting from the orlistat action mechanism that
can act as enhancers of the carcinogenesis process in other tissues,
as is the case with colorectal cancer (Garcia et al., 2006). Garcia
et al. (2006) have stated that the increase in the fat content in
the distal colon lumen, resulting from the action of orlistat, may
intensify the formation of aberrant cryptic foci (precursors of
lesions that develop colorectal cancer), increasing the epithelial
cell proliferation in the colon mucosa tissues. This action would
Table 4
Tumor clone frequency observed in Drosophila melanogaster, heterozygote for the wts tumor suppressor gene, pre-treated with mitomicin C (6 h) and subsequently treated with
different orlistat concentrations.
Treatment Number of ﬂies Number of tumors analyzed Frequency (No. of tumors/ﬂy)
Orlistat (mg/mL) MMC (mM) Eye Head Wing Body Leg Halter Total
0 0 200 0 10 11 7 17 1 46 0.23
0 0.1 200 15 89 261 223 121 14 723 3.62*
2.4 0 200 1 14 13 13 14 2 57 0.29 ns⁄
4.8 0 200 1 6 19 12 19 1 58 0.29 ns⁄
9.6 0 200 0 6 19 11 14 1 51 0.25 ns⁄
2.4 0.1 200 11 74 270 201 178 12 746 3.73 ns⁄⁄
4.8 0.1 200 19 86 277 185 164 17 748 3.74 ns⁄⁄
9.6 0.1 200 34 93 264 194 153 19 757 3.78 ns⁄⁄
Statistical diagnosis according to the Mann–Whitney Test. Level of signiﬁcance P 6 0.05.
ns⁄, values considered not signiﬁcant when compared to the negative control.
ns⁄⁄, values considered not signiﬁcant when compared to the positive control.
MMC, mitomicin C.
* Value consider different from the negative control (P 6 0.05).
P.C. Orsolin et al. / Food and Chemical Toxicology 50 (2012) 2598–2604 2603be mediated by an increase in free radical formation derived from
oxygen, associated with fat accumulation, in the feces. These re-
sults suggest that orlistat might play a double role in carcinogene-
sis. It was concluded that new research should be conducted to
advance understanding of the effects of orlistat and the increase
in fecal fat associated with its mechanism of action, to ensure
the safe use of orlistat by human beings.
Finally, we can conclude that, under the experimental condi-
tions and tested concentrations of the present study, orlistat had
a recombinagenic effect on somatic cells of D. melanogaster and
that this effect was associated with the transformation of cyto-
chrome P450. However, orlistat does not have carcinogenic poten-
tial and cannot reduce tumors induced by mitomicin C in
D. melanogaster.
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